19. Pulmonary Targeting of Nanoparticles and Monoclonal Antibodies

  1. Yashwant Pathak3 and
  2. Simon Benita4
  1. Weiyuan Chang

Published Online: 23 APR 2012

DOI: 10.1002/9781118229019.ch19

Antibody-Mediated Drug Delivery Systems: Concepts, Technology, and Applications

Antibody-Mediated Drug Delivery Systems: Concepts, Technology, and Applications

How to Cite

Chang, W. (2012) Pulmonary Targeting of Nanoparticles and Monoclonal Antibodies, in Antibody-Mediated Drug Delivery Systems: Concepts, Technology, and Applications (eds Y. Pathak and S. Benita), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9781118229019.ch19

Editor Information

  1. 3

    Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, Florida, USA

  2. 4

    The Institute for Drug Research of the School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

Author Information

  1. Department of Environmental and Occupational Health, School of Public Health, University of Louisville, Louisville, Kentucky, USA

  1. Division of Preclinical Science, Center For Drug Evaluation, Taipei, Taiwan

Publication History

  1. Published Online: 23 APR 2012
  2. Published Print: 11 MAY 2012

ISBN Information

Print ISBN: 9780470612811

Online ISBN: 9781118229019

SEARCH

Keywords:

  • pulmonary targeting of NPs and mAbs;
  • mAb attributes, as therapeutics in pulmonary diseases;
  • antibody-conjugated NPs in lung targeting;
  • cells, mediators in COPD, as targets for mAbs;
  • challenges in disease, nanocarriers in pulmonary clearance

Summary

This chapter contains sections titled:

  • Introduction

  • Attributes of mAbs as Therapeutics for Pulmonary Diseases

  • Antibody-Conjugated Nanoparticles for Lung Targeting

  • Monoclonal Antibodies in the Treatment of Asthma

  • Monoclonal Antibodies in the Treatment of COPD

  • Challenges in Pulmonary Disease

  • Conclusions

  • References